Personalized Medicine: Optimizing Outcomes for Patients with CLL

Opinion
Video

Nitin Jain, MD, presents data on the efficacy of various chronic lymphocytic leukemia treatments, reviews current guidelines, discusses the increasing use of Bruton's tyrosine kinase inhibitors and the decreasing role of chemotherapy in his practice. He emphasizes the importance of considering patient factors and preferences in treatment decision-making.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.